- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06337578
Advances in Telephone-based Cognitive Screening Procedures (TBCS)
Avanzamenti in Materia di Screening Cognitivo Telefonico
Background
Cognitive screening procedures via performance-based tests represent an essential, albeit preliminary, element within the diagnostic and interventional process as addressed to patients with chronic neurological disorders. Furthermore, in these populations, cognitive screening measures are often employed as outcomes in epidemiological settings, as well as endpoints in clinical trials. Therefore, cognitive screeners need to possess robust clinimetric and clinical usability properties - the investigation of which must be country-specific (i.e., specific to each language and culture).
The need for such clinimetric and feasibility studies is even more true if referred to telephone-based cognitive screening (TBCS) procedures - which, until recently, have been mostly neglected in Italy, despite having the potential to bring clear benefits to clinical practice and research. In fact, TBCS techniques allow, through the use of a very widespread, accessible and easy-to-use telecommunication medium, to break down the geographical, logistical, socio-demographic and organizational barriers that make it difficult and/or prevent 1) access to these clinical services and 2) the continuity of their provision, as well as the creation and completion of 3) large-scale epidemiological studies and 4) decentralized clinical trials. However, although some TBCS tests have recently been developed and standardized in Italy, their clinimetric properties and clinical usability in populations with chronic neurological disorders have not yet been investigated. Furthermore, currently, the "paper-and-pencil" version of the international gold-standard for TBCS procedures . i.e. the Telephone Interview For Cognitive Status (TICS), which has been recently standardized in this country - is not available within the Italian scenario. In fact, although the feasibility of a de visu version of the TICS (i.e., In-Person TICS; IP-TICS) has been demonstrated in this country, an actual standardization of this test has not yet been implemented to date. Such a tool would, however, allow flexible use of screening assessments, regardless of the delivery method, both in clinical and experimental contexts.
Aims
The present study primarily aims to provide exhaustive evidence regarding the psychometric, diagnostic and both cross-sectional and longitudinal clinical usability of TBCS that are currently available within the Italian scenario in populations with chronic neurological disorders. Secondly, this study aims to derive, in normotypical Italian subjects, 1) normative data for the IP-TICS and 2) the conversion algorithms between the latter (and other widely used "paper-and-pencil" screeners ) and the TICS.
- Methods
The study is monocentric, observational, prospective. Over a period of 3 years, patients who have already undergone an in-person cognitive screening session within 6 months prior to recruitment and falling under the following diagnostic categories will be recruited: 1) amyotrophic lateral sclerosis (N≥88); 2) Alzheimer's disease (N≥66); 3) Lewy body dementia (N≥30); 4) frontotemporal dementia (N≥30); 5) chronic cerebrovascular disorders (N≥66). Furthermore, N≥287 normotypical subjects representative of the Italian population will be recruited. The following TBCS tests will be administered to patients: 1) TICS; 2) Telephone-based Frontal Assessment Battery; 3) Telephone Language Screener; 4) Telephone-based Verbal Fluency Battery; 5) ALS Cognitive Behavioral Screen-Phone Version. Additionally, patients will undergo a functional evaluation using caregiver-report questionnaires evaluating instrumental and non-instrumental skills of daily living and behavioral changes. Normal subjects will instead be administered: 1) TICS; 2) IP-TICS; 3) Mini-Mental State Examination (MMSE); 4) Montreal Cognitive Assessment (MoCA). In patients, telephone follow-ups are expected after 6, 12 and 18 months. Statistical analyses will be carried out aimed at 1) the detailed study, in patients, of the psychometrics, diagnostics and cross-sectional/longitudinal clinical usability of the aforementioned TBCS test, as well as at 2) the derivation, in normotypical subjects, of the normative data of the IP-TICS and MoCA Memory Index Score (MIS), as well as the conversion algorithms between TICS and IP-TICS/MMSE/MoCA.
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Barbara Poletti, Ph.D.
- Phone Number: 2609 +390261911
- Email: b.poletti@auxologico.it
Study Locations
-
-
-
Milano, Italy, 20149
- Recruiting
- Istituto Auxologico Italiano
-
Contact:
- Barbara Poletti, Ph.D.
- Phone Number: 2609 +390261911
- Email: b.poletti@auxologico.it
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion criteria:
Patient cohorts: diagnosis of interest. NIs: not applicable
Exclusion Criteria:
Patient cohorts
- age <18 years;
- denial of informed consent to voluntary participation and data processing;
- absence of the diagnosis of interest;
- absence of a de visu cognitive screening assessment carried out in the 6 months prior to recruitment;
- positive history of 1) psychiatric pathologies, 2) serious and/or uncompensated general-medical conditions and 3) uncorrected visual/hearing deficits.
NIs:
- age <18 years;
- denial of informed consent to voluntary participation and data processing;
- positive history of 1) brain disorders, 2) serious and/or uncompensated general-medical conditions and 3) uncorrected visual/hearing deficits.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Patients with amyotrophic lateral sclerosis (ALS)
Individuals having been received a clinical diagnosis of amyotrophic lateral sclerosis according to current diagnostic criteria
|
ALS patients will be administered the following TBCS tests:
This group will also undergo a telephone-based, caregiver-reported behavioral and functional assessment via the following scales:
|
|
Patients with Alzheimer's disease (AD)
Individuals having been received a neurochemical and/or aclinical diagnosis of Alzheimer's according to current diagnostic criteria
|
AD, DLB, FTD and CVD patients will be administered the following TBCS tests:
These groups will also undergo a telephone-based, caregiver-reported behavioral and functional assessment via the following scales:
|
|
Patients with Lewy body dementia (LBD)
Individuals having been received a clinical diagnosis of Lewy body dementia according to current diagnostic criteria
|
AD, DLB, FTD and CVD patients will be administered the following TBCS tests:
These groups will also undergo a telephone-based, caregiver-reported behavioral and functional assessment via the following scales:
|
|
Patients with frontotemporal dementia (FTD)
Individuals having been received a clinical diagnosis of frontotemporal dementia (i.e., behavioural variant-frontotemporal dementia; semantic dementia; progressive non-fluent aphasia) according to current diagnostic criteria
|
AD, DLB, FTD and CVD patients will be administered the following TBCS tests:
These groups will also undergo a telephone-based, caregiver-reported behavioral and functional assessment via the following scales:
|
|
Patients with chronic cerebrovascular disorders (CVD)
Individuals with mild cognitive impairment/dementia and neuroradiological evidence of chronic cerebrovascular diseases
|
AD, DLB, FTD and CVD patients will be administered the following TBCS tests:
These groups will also undergo a telephone-based, caregiver-reported behavioral and functional assessment via the following scales:
|
|
Normotypical individuals (NI)
Individuals without brain disorders
|
NIs will undergo the Telephone Interview for Cognitive Status over the telephone and will be additionally administered, in person, the following cognitive screeners:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
ALS Cognitive Behavioral Screen-Phone Version in ALS patients
Time Frame: At enrollment and at 6 months, 12 months and 18 months of follow-up
|
ALS Cognitive Behavioral Screen-Phone Version
|
At enrollment and at 6 months, 12 months and 18 months of follow-up
|
|
Telephone Interview for Cognitive Status in AD, LBD, FTD and CVD patients
Time Frame: At enrollment and at 6 months, 12 months and 18 months of follow-up
|
Telephone Interview for Cognitive Status
|
At enrollment and at 6 months, 12 months and 18 months of follow-up
|
|
Telephone-based Frontal Assessment Battery in ALS, AD, LBD, FTD and CVD patients
Time Frame: At enrollment and at 6 months, 12 months and 18 months of follow-up
|
Telephone-based Frontal Assessment Battery
|
At enrollment and at 6 months, 12 months and 18 months of follow-up
|
|
Telephone Language Screener in ALS, AD, LBD, FTD and CVD patients
Time Frame: At enrollment and at 6 months, 12 months and 18 months of follow-up
|
Telephone Language Screener
|
At enrollment and at 6 months, 12 months and 18 months of follow-up
|
|
Telephone-based Verbal Fluency Battery in ALS, AD, LBD, FTD and CVD patients
Time Frame: At enrollment and at 6 months, 12 months and 18 months of follow-up
|
Telephone-based Verbal Fluency Battery
|
At enrollment and at 6 months, 12 months and 18 months of follow-up
|
|
Mini-Mental State Examination in NI
Time Frame: At enrollment and at 6 months, 12 months and 18 months of follow-up
|
Mini-Mental State Examination; test with minimum score of 0 and maximum score of 30
|
At enrollment and at 6 months, 12 months and 18 months of follow-up
|
|
Montreal Cognitive Assessment in NI
Time Frame: At enrollment and at 6 months, 12 months and 18 months of follow-up
|
Montreal Cognitive Assessment; test with maximum score of 30: score of 26 or more is considered normal
|
At enrollment and at 6 months, 12 months and 18 months of follow-up
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Cardiovascular Diseases
- Vascular Diseases
- Metabolic Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurocognitive Disorders
- Neuromuscular Diseases
- Parkinsonian Disorders
- Basal Ganglia Diseases
- Movement Disorders
- Synucleinopathies
- Neurodegenerative Diseases
- Spinal Cord Diseases
- TDP-43 Proteinopathies
- Proteostasis Deficiencies
- Dementia
- Tauopathies
- Motor Neuron Disease
- Amyotrophic Lateral Sclerosis
- Alzheimer Disease
- Lewy Body Disease
- Cerebrovascular Disorders
Other Study ID Numbers
- 23C308
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cerebrovascular Disorders
-
Peking University Third HospitalBeijing HospitalCompletedCerebrovascular DiseasesChina
-
University Health Network, TorontoEisai Inc.CompletedDementia Associated With Cerebrovascular DiseaseCanada
-
Eisai Co., Ltd.CompletedA Study of Donepezil Hydrochloride in Patients With Dementia Associated With Cerebrovascular DiseaseDementia Associated With Cerebrovascular DiseaseKorea, Republic of
-
Assistance Publique - Hôpitaux de ParisActive, not recruiting
-
National Taiwan University HospitalNational Science Council, TaiwanUnknown
-
Gansu Provincial Maternal and Child Health Care...Not yet recruiting
-
First Affiliated Hospital of Harbin Medical UniversityRecruitingCerebrovascular Disease Small VesselChina
-
National Taiwan University HospitalNational Science Council, TaiwanUnknownCerebrovascular AccidentsTaiwan
-
Chinese PLA General HospitalNot yet recruitingCardiovascular and Cerebrovascular Diseases
-
University of Alabama at BirminghamCompleted
Clinical Trials on Telephone-based neuropsychological assessment - ALS
-
IRCCS San Camillo, Venezia, ItalyUnknown
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedStage I Breast Cancer | Stage II Breast Cancer | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage III Colorectal Cancer AJCC v7 | Stage IIIA Colorectal Cancer AJCC v7 | Stage IIIB Colorectal Cancer... and other conditionsUnited States
-
IRCCS San RaffaeleRecruitingEpilepsy | Focal EpilepsyItaly
-
IRCCS San RaffaeleRecruiting
-
IRCCS San Camillo, Venezia, ItalyActive, not recruitingHealthy | Traumatic Brain Injury | Mild Cognitive Impairment | Right Hemispheric Stroke | Left Hemispheric Stroke | Right Hemispheric Brain Tumor | Left Hemispheric Brain TumorItaly
-
University Hospital, Strasbourg, FranceCompletedParkinson Disease DementiaFrance
-
IRCCS Eugenio MedeaUniversity of Geneva, Switzerland; Scuola Universitaria Professionale della...Not yet recruitingNeurodevelopmental Disorder (Diagnosis)
-
Charite University, Berlin, GermanyRecruiting
-
Region SkaneLund University; Aarhus University Hospital; Mid and South Essex NHS Foundation... and other collaboratorsCompletedFatigue | Insomnia | Cognition Disorders | Psychological Distress | Hypoxia-Ischemia, Brain | Heart Arrest, Out-Of-HospitalSweden, Denmark, United Kingdom
-
Uppsala UniversityCompleted